5-Aminosalicylate (5-ASA)
https://libcat.nshealth.ca/en/permalink/chpams35397
Nova Scotia Health Authority. Central Zone. Gastroenterology.
Halifax, NS:
Nova Scotia Health Authority
, 2016.
- Pamphlet Number
- 1483
- Available Online
- View Pamphlet
5-aminosalicylate (5-ASA) is a type of drug often used to treat inflammatory bowel disease (IBD). This type of drug is good at controlling active ulcerative colitis or Crohn’s colitis as well as keeping ulcerative colitis in remission. Topics include: what 5-ASA type drugs do, which 5-ASA you should take, continuing to take the drug, talking to your doctor, what other medication you can take, and when to expect to see improvement. The pamphlet also describes common and rare side effects.
- Available Online
- View Pamphlet
- Corporate Author
- Nova Scotia Health Authority. Central Zone. Gastroenterology
- Place of Publication
- Halifax, NS
- Publisher
- Nova Scotia Health Authority
- Date of Publication
- 2016
- Format
- Pamphlet
- Language
- English
- Physical Description
- 1 electronic document (6 p.) : digital, PDF file
- Subjects (MeSH)
- Inflammatory Bowel Diseases - drug therapy
- Crohn Disease - drug therapy
- Colitis - drug therapy
- Subjects (LCSH)
- Inflammatory bowel diseases
- Crohn's disease
- Colitis
- Abstract
- 5-aminosalicylate (5-ASA) is a type of drug often used to treat inflammatory bowel disease (IBD). This type of drug is good at controlling active ulcerative colitis or Crohn’s colitis as well as keeping ulcerative colitis in remission. Topics include: what 5-ASA type drugs do, which 5-ASA you should take, continuing to take the drug, talking to your doctor, what other medication you can take, and when to expect to see improvement. The pamphlet also describes common and rare side effects.
- Responsibility
- Prepared by: Jennifer Stewart, RN; Gastroenterology
- Prepared by: Kaleigh MacIsaac, B.ScPharm; Gastroenterology
- Revised by: Phyllis Durning, RN
- Revised by: Alison Harding, B.Sc.
- Pamphlet Number
- 1483
Diet guidelines for ileoanal pouch
https://libcat.nshealth.ca/en/permalink/chpams35061
Nova Scotia Health Authority. Central Zone. Food and Nutrition Services.
Halifax, NS:
Nova Scotia Health Authority
, 2016.
- Pamphlet Number
- 0555
- Available Online
- View Pamphlet
Tips to control gas, bloating, and diarrhea are given. Good food choices after surgery are listed as well as a list of foods to stay away from for at least 4 weeks after surgery.
- Available Online
- View Pamphlet
- Place of Publication
- Halifax, NS
- Publisher
- Nova Scotia Health Authority
- Date of Publication
- 2016
- Format
- Pamphlet
- Language
- English
- Physical Description
- 1 electronic document (5 p.) : digital, PDF file
- Subjects (LCSH)
- Restorative Proctocolectomy
- Digestive organs--Diseases
- Specialty
- Food and nutrition
- Abstract
- Tips to control gas, bloating, and diarrhea are given. Good food choices after surgery are listed as well as a list of foods to stay away from for at least 4 weeks after surgery.
- Responsibility
- Prepared by: Food and Nutrition Services
- Pamphlet Number
- 0555
Ulcerative proctitis
https://libcat.nshealth.ca/en/permalink/chpams35311
Nova Scotia Health Authority. GI Clinic.
Halifax, NS:
Nova Scotia Health Authority
, 2021.
- Pamphlet Number
- 1422
- Available Online
- View Pamphlet
Ulcerative proctitis is a type of inflammatory bowel disease. Inflammatory bowel disease (IBD) is the general name for diseases that cause inflammation (swelling and irritation) in the intestines (“gut”). It includes ulcerative proctitis, Crohn’s disease, and ulcerative colitis. How this condition is diagnosed as well as the symptoms and treatments are reviewed.
- Available Online
- View Pamphlet
- Corporate Author
- Nova Scotia Health Authority. GI Clinic
- Place of Publication
- Halifax, NS
- Publisher
- Nova Scotia Health Authority
- Date of Publication
- 2021
- Format
- Pamphlet
- Language
- English
- Physical Description
- 1 electronic document (4 p.) : digital, PDF file
- Subjects (MeSH)
- Colitis, Ulcerative
- Inflammatory Bowel Diseases
- Subjects (LCSH)
- Ulcerative colitis
- Inflammatory bowel diseases
- Abstract
- Ulcerative proctitis is a type of inflammatory bowel disease. Inflammatory bowel disease (IBD) is the general name for diseases that cause inflammation (swelling and irritation) in the intestines (“gut”). It includes ulcerative proctitis, Crohn’s disease, and ulcerative colitis. How this condition is diagnosed as well as the symptoms and treatments are reviewed.
- Responsibility
- Prepared by: GI Clinic
- Pamphlet Number
- 1422
Vedolizumab (Entyvio) therapy
https://libcat.nshealth.ca/en/permalink/chpams35620
Nova Scotia Health Authority. Nova Scotia Collaborative IBD Program.
Halifax, NS:
Nova Scotia Health Authority
, 2022.
- Pamphlet Number
- 1623
- Available Online
- View Pamphlet
Vedolizumab (Entyvio®) is given to manage inflammatory bowel disease (IBD), ulcerative colitis, or Crohn's disease. This pamphlet gives you information about vedolizumab to help you make an informed decision about whether or not to use it. Topics include: a brief description of the medicine, who can take it, how it works, how it is given, how long you will need to take it, cost, precautions, and side effects. A list of symptoms to watch out for is listed. Other important things to know when und…
- Available Online
- View Pamphlet
- Corporate Author
- Nova Scotia Health Authority. Nova Scotia Collaborative IBD Program
- Place of Publication
- Halifax, NS
- Publisher
- Nova Scotia Health Authority
- Date of Publication
- 2022
- Format
- Pamphlet
- Language
- English
- Physical Description
- 1 electronic document (11 p.) : digital, PDF file
- Subjects (MeSH)
- Gastrointestinal Agents
- Colitis, Ulcerative - drug therapy
- Crohn Disease - drug therapy
- Subjects (LCSH)
- Gastrointestinal agents
- Ulcerative colitis
- Crohn's disease
- Specialty
- Medications
- Abstract
- Vedolizumab (Entyvio®) is given to manage inflammatory bowel disease (IBD), ulcerative colitis, or Crohn's disease. This pamphlet gives you information about vedolizumab to help you make an informed decision about whether or not to use it. Topics include: a brief description of the medicine, who can take it, how it works, how it is given, how long you will need to take it, cost, precautions, and side effects. A list of symptoms to watch out for is listed. Other important things to know when undergoing this treatment are provided.
- Responsibility
- Prepared by: Nova Scotia Collaborative IBD Program
- Pamphlet Number
- 1623
